Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.
Lishi LinHannerieke J BarkmanEgbert F SmitAdrianus J de LangenNeeltje SteeghsJos H BeijnenAlwin D R HuitemaPublished in: Therapeutic drug monitoring (2023)
For alectinib, high Cmin,ss was correlated with a higher risk of DLT. No differences in the frequency of DLTs were observed between the high and non-high groups for crizotinib, osimertinib, dabrafenib, and trametinib.